Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
Revenues		$ 496,100,000	$ 452,000,000.0	$ 1,311,800,000	$ 1,314,200,000
Operating expenses:
Salaries and benefits		141,700,000	139,300,000	398,200,000	401,200,000
Supplies		142,800,000	126,200,000	382,200,000	364,600,000
Professional and medical fees		46,300,000	38,500,000	138,400,000	110,000,000.0
Lease expense		21,900,000	21,400,000	64,700,000	63,000,000.0
Other operating expenses		29,200,000	27,700,000	83,900,000	80,800,000
Cost of revenues		381,900,000	353,100,000	1,067,400,000	1,019,600,000
General and administrative expenses		25,200,000	19,900,000	73,300,000	64,900,000
Depreciation and amortization		24,100,000	18,400,000	69,300,000	56,300,000
Income from equity investments		(3,100,000)	(2,400,000)	(7,600,000)	(6,600,000)
Loss (gain) on disposals and deconsolidations, net		700,000	600,000	7,100,000	(7,000,000.0)
Transaction and integration costs		5,400,000	3,400,000	15,800,000	11,600,000
Impairment charges		33,500,000	0	33,500,000	0
Grant funds		9,900,000	0	(33,200,000)	0
Litigation settlement		0	0	1,200,000	0
Loss on debt extinguishment		0	0	0	11,700,000
Other income		0	0	(1,700,000)	(400,000)
Total operating expenses		477,600,000	393,000,000.0	1,225,100,000	1,150,100,000
Operating income		18,500,000	59,000,000.0	86,700,000	164,100,000
Tax receivable agreement expense		0	0	0	(2,400,000)
Interest expense, net		(51,500,000)	(45,700,000)	(147,800,000)	(134,100,000)
(Loss) income before income taxes		(33,000,000.0)	13,300,000	(61,100,000)	27,600,000
Income tax expense (benefit)		1,300,000	2,400,000	(14,500,000)	5,100,000
Net (loss) income		(34,300,000)	10,900,000	(46,600,000)	22,500,000
Less: Net income attributable to non-controlling interests		(27,300,000)	(26,600,000)	(75,000,000.0)	(78,100,000)
Net loss attributable to Surgery Partners, Inc.		(61,600,000)	(15,700,000)	(121,600,000)	(55,600,000)
Less: Amounts attributable to participating securities		(10,000,000.0)	(9,100,000)	(29,200,000)	(26,400,000)
Net loss attributable to common stockholders		$ (71,600,000)	$ (24,800,000)	$ (150,800,000)	$ (82,000,000.0)
Net loss per share attributable to common stockholders
Basic (in USD per share)		$ (1.46)	$ (0.51)	$ (3.09)	$ (1.70)
Diluted (in USD per share)	[1]	$ (1.46)	$ (0.51)	$ (3.09)	$ (1.70)
Weighted average common shares outstanding
Basic (shares)		48,883	48,310	48,736	48,265
Diluted (shares)	[1]	48,883	48,310	48,736	48,265

[1] The impact of potentially dilutive securities for all periods presented was not considered because the effect would be anti-dilutive in those periods.